Gentamicin-loaded nanoparticles show improved antimicrobial effects towards Pseudomonas aeruginosa infection

International Journal of Nanomedicine

Volumn 7, Issue , 2012, Pages 4053-4063

  Abdelghany, Sharif M ^a   Quinn, Derek J ^a   Ingram, Rebecca J ^a   Gilmore, Brendan F ^a   Donnelly, Ryan F ^a   Taggart, Clifford C ^a   Scott, Christopher J ^a  

^a QUEEN'S UNIVERSITY BELFAST   (United Kingdom)

Author keywords

Anti microbial; Gentamicin; PLGA nanoparticles; Pseudomonas aeruginosa

Indexed keywords

GENTAMICIN; INTERLEUKIN 6; MYELOPEROXIDASE; POLYGLACTIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBACTERIAL ACTIVITY; ARTICLE; BACTERIAL PERITONITIS; BACTERIUM CULTURE; BIOFILM; COLONY FORMING UNIT; CONTROLLED STUDY; DRUG CLEARANCE; DRUG CONCENTRATION; DRUG DOSAGE FORM COMPARISON; DRUG EFFECT; DRUG EFFICACY; DRUG FORMULATION; FEMALE; HYDROPHILICITY; IN VITRO STUDY; IN VIVO STUDY; MINIMUM BACTERICIDAL CONCENTRATION; MINIMUM BIOFILM ERADICATION CONCENTRATION; MINIMUM INHIBITORY CONCENTRATION; MOUSE; NONHUMAN; PARTICLE SIZE; PERITONEUM LAVAGE; PH; PSEUDOMONAS INFECTION; SOLID IN OIL IN WATER FORMULATION; SUSTAINED DRUG RELEASE; WATER IN OIL IN WATER FORMULATION;

ANIMALS; ANTI-BACTERIAL AGENTS; BIOFILMS; COLONY COUNT, MICROBIAL; FEMALE; GENTAMICINS; HYDROGEN-ION CONCENTRATION; HYDROPHOBIC AND HYDROPHILIC INTERACTIONS; LACTIC ACID; MICE; MICROBIAL SENSITIVITY TESTS; NANOPARTICLES; POLYGLYCOLIC ACID; PSEUDOMONAS AERUGINOSA; PSEUDOMONAS INFECTIONS;

MURINAE; PSEUDOMONAS; PSEUDOMONAS AERUGINOSA;

EID: 84870345659     PISSN: 11769114     EISSN: 11782013     Source Type: Journal    
DOI: 10.2147/IJN.S34341     Document Type: Article

References (37)

1. Rusin PA, Rose JB, Haas CN, Gerba CP. Risk assessment of opportunistic bacterial pathogens in drinking water. Rev Environ Contam Toxicol. 1997;152:57-83.
2. Degoricija V, Skerk V, Vatavuk Z, Knezević T, Sefer S, Vućicević Z. Bilateral Pseudomonas aeruginosa endogenous endophthalmitis in an immune-competent patient with nosocomial urosepsis following abdominal surgery. Acta Clin Croat. 2011;50:261-266.
3. Wildeboer D, Hill KE, Jeganathan F, etal. Specific protease activity indicates the degree of Pseudomonas aeruginosa infection in chronic infected wounds. Eur J Clin Microbiol Infect Dis. 2012;0934-9723: 1-7.
4. Dickinson GM, Bisno AL. Infections associated with indwelling devices: Infections related to extravascular devices. Antimicrob Agents Chemother. 1989;33:602-607.
5. Schryvers AB, Ogunariwo J, Chamberland S, Godfrey AJ, Rabin HR, Bryan LE. Mechanism of Pseudomonas aeruginosa persistence during treatment with broad-spectrum cephalosporins of lung infections in patients with cystic fibrosis. Antimicrob Agents Chemother. 1987;31: 1438-1439.
6. Weber DJ, Rutala WA, Sickbert-Bennett EE, Samsa GP, Brown V, Niederman MS. Microbiology of ventilator-associated pneumonia compared with that of hospital-acquired pneumonia. Infect Control Hosp Epidemiol. 2007;28:825-831.
7. Cross A, Allen JR, Burke J, etal. Nosocomial infections due to Pseudomonas aeruginosa: review of recent trends. Rev Infect Dis. 1983;5 Suppl:S837-S845.
8. Saiman L. Infection prevention and control in cystic fibrosis. Curr Opin Infect Dis. 2011;24:390-395.
9. Lang AB, Horn MP, Imboden MA, Zuercher AW. Prophylaxis and therapy of pseudomonas aeruginosa infection in cystic fibrosis and immunocompromised patients. Vaccine. 2004;22 Suppl:S44-S48.
10. Yoshizawa S, Fourmy D, Puglisi JD. Structural origins of gentamicin antibiotic action. EMBO J. 1998;17:6437-6448.
11. Tange RA, Dreschler WA, Prins JM, Buller HR, Kuijper EJ, Speelman P. Ototoxicity and nephrotoxicity of gentamicin vs netilmicin in patients with serious infections. a randomized clinical trial. Clin Otolaryngol Allied Sci. 1995;20:118-123.
12. Lećaroz C, Blanco-Prieto MJ, Burrell MA, Gamazo C. Intracellular killing of Brucella melitensis in human macrophages with microsphere-encapsulated gentamicin. J Antimicrob Chemother. 2006;58:549-556.
13. Lu E, Franzblau S, Onyuksel H, Popescu C. Preparation of aminoglycoside-loaded chitosan nanoparticles using dextran sulphate as a counterion. J Microencapsul. 2009;26:346-354.
14. Soliman GM, Szychowski J, Hanessian S, Winnik FM. Robust polymeric nanoparticles for the delivery of aminoglycoside antibiotics using carboxymethyldextran-b-poly(ethyleneglycols) lightly grafted with n-dodecyl groups. Soft Matter. 2010;6:4504-4514.
15. Pinto-Alphandary H, Andremont A, Couvreur P. Targeted delivery of antibiotics using liposomes and nanoparticles: research and applications. Int J Antimicrob Agents. 2000;13:155-168.
16. Couvreur P, Fattal E, Andremont A. Liposomes and nanoparticles in the treatment of intracellular bacterial infections. Pharm Res. 1991;8: 1079-1086.
17. Gao P, Nie X, Zou M, Shi Y, Cheng G. Recent advances in materials for extended-release antibiotic delivery system. J Antibiot (Tokyo). 2011;64:625-634.
18. Seleem MN, Munusamy P, Ranjan A, Alqublan H, Pickrell G, Sriranganathan N. Silica-antibiotic hybrid nanoparticles for targeting intracellular pathogens. Antimicrob Agents Chemother. 2009;53:4270-4274.
19. Mohammadi G, Valizadeh H, Barzegar-Jalali M, etal. Development of azithromycin-PLGA nanoparticles: Physicochemical characterization and antibacterial effect against Salmonella typhi. Colloids Surf B Biointerfaces. 2010;80:34-39.
20. Pillai RR, Somayaji SN, Rabinovich M, Hudson MC, Gonsalves KE. Nafcillin-loaded PLGA nanoparticles for treatment of osteomyelitis. Biomed Mater. 2008;3:034114.
21. Kashi TS, Eskandarion S, Esfandyari-Manesh M, etal. Improved drug loading and antibacterial activity of minocycline-loaded PLGA nanoparticles prepared by solid/oil/water ion pairing method. Int J Nanomedicine. 2012;7:221-234.
22. Benson JR, Hare PE. O-phthalaldehyde: Fluorogenic detection of primary amines in the picomole range. Comparison with fluorescamine and ninhydrin. Proc Natl Acad Sci U S A. 1975;72:619-622.
23. Fay F, Quinn DJ, Gilmore BF, McCarron PA, Scott CJ. Gene delivery using dimethyldidodecylammonium bromide-coated PLGA nanoparticles. Biomaterials. 2010;31:4214-4222.
24. Khan W, Bernier SP, Kuchma SL, Hammond JH, Hasan F, O'Toole GA. Aminoglycoside resistance of Pseudomonas aeruginosa biofilms modulated by extracellular polysaccharide. Int Microbiol. 2010;13: 207-212.
25. Ceri H, Olson ME, Stremick C, Read RR, Morck D, Buret A. The Calgary Biofilm Device: New technology for rapid determination of antibiotic susceptibilities of bacterial biofilms. J Clin Microbiol. 1999;37:1771-1776.
26. Trnovec T, Durisová M, Bezek S, etal. Pharmacokinetics of gentamicin administered intratracheally or as an inhalation aerosol to guinea pigs. Drug Metab Dispos. 1984;12:641-644.
27. Di Roccoa PH, Nacucchio MC, Sordelli DO. Aerosol treatment with cefoperazone or gentamicin protects granulocytopenic mice from acute Pseudomonas aeruginosa pneumonia. Eur J Pharm Sci. 1994;1:285-289.
28. Lü JM, Wang X, Marin-Muller C, etal. Current advances in research and clinical applications of PLGA-based nanotechnology. Expert Rev Mol Diagn. 2009;9:325-341.
29. Danhier F, Ansorena E, Silva JM, Coco R, Le Breton A, Préat V. PLGA-based nanoparticles: an overview of biomedical applications. J Control Release. 2012;16:505-522.
30. Giteau A, Venier-Julienne MC, Marchal S, etal. Reversible protein precipitation to ensure stability during encapsulation within PLGA microspheres. Eur J Pharm Biopharm. 2008;70:127-136.
31. Song X, Zhao Y, Hou S, etal. Dual agents loaded PLGA nanoparticles: systematic study of particle size and drug entrapment efficiency. Eur J Pharm Biopharm. 2008;69:445-453.
32. Smith AL, Daum RS, Siber GR, Scheifele DW, Syriopoulou VP. Gentamicin penetration into cerebrospinal fluid in experimental Haemophilus influenzae meningitis. Antimicrob Agents Chemother. 1988;32:1034-1039.
33. Rukholm G, Mugabe C, Azghani AO, Omri A. Antibacteria activity of liposomal gentamicin on pseudomonas aeruginosa: A time-kill study. Int J Antimicrob Agents. 2006;27:247-252.
34. Owens DE 3rd, Peppas NA. Opsonization, biodistribution, and pharmacokinetics of polymeric nanoparticles. Int J Pharm. 2006;307(1): 93-102.
35. Semete B, Booysen L, Lemmer Y, etal. In vivo evaluation of the biodistribution and safety of PLGA nanoparticles as drug delivery systems. Nanomedicine. 2010;6:662-671.
36. Rao SC, Srinivasjois R, Hagan R, Ahmed M. One dose per day compared to multiple doses per day of gentamicin for treatment of suspected or proven sepsis in neonates. Cochrane Database Syst Rev. 2011;11:CD005091.
37. Best EJ, Gazarian M, Cohn R, Wilkinson M, Palasanthiran P. Once-daily gentamicin in infants and children: A prospective cohort study evaluating safety and the role of therapeutic drug monitoring in minimizing toxicity. Pediatr Infect Dis J. 2011;30:827-832.